Asthma Management Guidelines and Steps
Uploaded by
salma nouseirAsthma Management Guidelines and Steps
Uploaded by
salma nouseirCommon questions
Powered by AIManagement strategies for asthma are stratified based on the severity of symptoms. For mild asthma, low-dose ICS whenever SABA is taken is recommended as the first step . Moderate asthma involves a progression to a daily low-dose ICS-LABA combination, with the option to add LTRA or SLIT HDM . Severe asthma requires more intensive interventions such as medium/high-dose ICS-LABA, and options for phenotypic assessment for biological therapies like SC anti-IgE, SC anti-IL5 for eosinophilic asthma, and other advanced treatment options . Additionally, all levels stress the importance of checking adherence, environmental control, and assessing for comorbid conditions .
MART, or Maintenance and Reliever Therapy, involves using the combination ICS-formoterol as both a daily controller and as-needed reliever. This approach aims to streamline treatment, improve adherence, and enhance outcomes. It is mainly utilized in Track 1, where formoterol's rapid onset of action makes it suitable for immediate relief as well as ongoing inflammation management . The guidelines provide dosage specifics such as a very low dose ICS-formoterol MART at 80/4.5 mcg per inhalation for sufficiency in symptom control .
Phenotypic assessment plays a critical role in guiding the use of biological therapies in severe asthma. It is typically recommended when conventional therapy does not adequately control symptoms . Biological options such as SC anti-IgE for allergic asthma, SC anti-IL5 for eosinophilic types, and SC anti-IL4 dupilumab for eosinophilic/Type 2 asthma hinge on accurately identifying the asthma phenotype, as these therapies target specific molecular pathways .
For children aged 6-11, low-dose budesonide/formoterol HFA MDI is recommended at a dose of 80/4.5 mcg, with 1 inhalation twice daily . In contrast, adults may use higher doses, such as fluticasone/salmeterol DPI Diskus at 250/50 mcg, or budesonide/formoterol 160/4.5 mcg with 2 inhalations twice daily . The recommendations for children emphasize lower doses, reflecting a tailored approach to avoid potential side effects associated with higher medication exposure in the pediatric population.
LTRA, such as montelukast, is integrated as an additional controller option when basic ICS or ICS-LABA combinations do not suffice. It is recommended for various situations: as a daily add-on to low-dose ICS, in conjunction with SLIT HDM, and for those who have persistent symptoms despite other therapies . The inclusion of LTRA provides a non-steroidal option that can help manage specific asthma components, such as exercise-induced symptoms or allergic rhinitis, thereby enhancing overall control.
Therapy is stepped up if asthma symptoms suggest inadequate control, prior to which adherence, environmental factors, and comorbid conditions should be assessed . Conversely, stepping down is appropriate if asthma is well-controlled for at least three months, allowing for possible reduction in medication dosage to minimize side effects while maintaining control . This approach is consistent across age groups and aims to personalize management to each patient's situation.
Tiotropium is recommended as an add-on treatment for patients aged 6 years and older at step 5 if asthma is not controlled by conventional therapies . For adults ≥18 years, azithromycin is considered as an add-on option for persisting asthma symptoms occurring despite optimized control measures, typically given 3 times a week . These medications are particularly useful in severe asthma to reduce exacerbations and enhance control.
In adults, asthma is considered well-controlled when daytime symptoms occur no more than twice per week, there are no nighttime awakenings due to asthma, reliever use is infrequent, and there are no activity limitations due to asthma . Conversely, if two of these criteria are not met, the asthma is partially controlled; if three or four are not met, it is uncontrolled.
For children under 5, the guidelines focus on minimal intervention due to the age-specific considerations. Asthma in this age group is managed by ensuring daytime symptoms occur only once a week for a few minutes, there are no nighttime manifestations, relievers are used infrequently, and overall, there is no activity limitation . Step-ups in therapy are closely monitored, with emphasis on verifying inhaler technique and assessing for other underlying conditions before adjusting the medication .
Before stepping up asthma therapy, the guidelines recommend checking for adherence to current treatment, ensuring correct inhaler technique, reviewing potential environmental triggers, and evaluating for any comorbid conditions that might be affecting control . This ensures that asthma exacerbations are truly due to inadequate control and not external factors or improper management of existing therapy.